Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014
Publication Date Jun 2014
Product Type Report
Pages 56
Single User License help $ 1500.00
Site User License help $ 3000.00
Corporate User License help $ 4500.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Sarepta Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sarepta Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sarepta Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sarepta Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Sarepta Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Sarepta Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sarepta Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sarepta Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sarepta Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sarepta Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sarepta Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Sarepta Therapeutics, Inc. Snapshot 6
Sarepta Therapeutics, Inc. Overview 6
Key Information 6
Key Facts 6
Sarepta Therapeutics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Sarepta Therapeutics, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Sarepta Therapeutics, Inc. - Pipeline Products Glance 12
Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Sarepta Therapeutics, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Sarepta Therapeutics, Inc. - Drug Profiles 16
eteplirsen 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AVI-7288 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
radavirsen 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AVI-6006 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AVI-7012 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Bacterial PPMO 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SRP-4044 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SRP-4045 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SRP-4050 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SRP-4053 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Antisense Oligonucleotide for Infectious Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Antisense Oligonucleotide for Rare Diseases 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SRP-4008 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SRP-4052 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SRP-4055 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Viral PMO-X 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Sarepta Therapeutics, Inc. - Pipeline Analysis 34
Sarepta Therapeutics, Inc. - Pipeline Products by Target 34
Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration 35
Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type 36
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action 37
Sarepta Therapeutics, Inc. - Recent Pipeline Updates 38
Sarepta Therapeutics, Inc. - Dormant Projects 49
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
AVI-4065 50
AVI-5126 50
AVI-6002 50
AVI-7537 51
Sarepta Therapeutics, Inc. - Company Statement 52
Sarepta Therapeutics, Inc. - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
List of Tables
Sarepta Therapeutics, Inc., Key Information 6
Sarepta Therapeutics, Inc., Key Facts 6
Sarepta Therapeutics, Inc. - Pipeline by Indication, 2014 9
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2014 10
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 11
Sarepta Therapeutics, Inc. - Phase II, 2014 12
Sarepta Therapeutics, Inc. - Phase I, 2014 13
Sarepta Therapeutics, Inc. - Preclinical, 2014 14
Sarepta Therapeutics, Inc. - Discovery, 2014 15
Sarepta Therapeutics, Inc. - Pipeline by Target, 2014 34
Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2014 35
Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2014 36
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 37
Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2014 38
Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2014 49
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2014 50
Sarepta Therapeutics, Inc., Other Locations 54

List of Figures
List of Figures
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 8
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2014 10
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 11
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 34
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 35
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 36
Sarepta Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 37

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
Global Dental Laboratory Handpieces Consumption 2016 Market Research Report
By QYResearch
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market. First, the report ...Read More
Jan 2016 $4000.00
Back to Report Store Home Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Description Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Mar 2017 $3995.00
Back to Report Store Home Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
By GBI Research
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation
By GBI Research
Description Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need
By GBI Research
The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three ...Read More
Aug 2017 $6995.00
Back to Report Store Home Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
By GBI Research
Description Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
By GBI Research
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential
By GBI Research
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Jan 2017 $6995.00
Back to Report Store Home Global Immunology Drugs Market to 2022-Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth
By GBI Research
Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation ...Read More
May 2017 $4995.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  Global Markets Direct

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z